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Abstract
Objectives. PsA and AS are chronic diseases associated with significant morbidities. National and in-
ternational management guidelines include treatment with biologic therapies to improve outcomes and
quality of life. There are limited real-world data on the patients’ journey from symptom onset to diag-
nosis and treatment in the UK. We use real-life, linked health data to explore patient pathways and the
impact of biologics on patient outcomes.
Methods. Data from the Secure Anonymised Information Linkage databank in Wales were used to as-
sess diagnosis and treatment of patients 18 years of age with at least one International Classification of
Diseases, Tenth Revision code present for PsA/AS in rheumatology clinic data and at least one Read
code present in primary care records. We investigated the use of biologics while exploring demographics,
comorbidities and surgical procedures of 641 AS patients and 1312 PsA patients.
Results. AS patients were significantly younger at diagnosis and were predominantly male. The aver-
age time from presenting symptoms to diagnosis of AS and PsA was 7.9 (S.D. 5.5) and 9.3 (S.D.
5.5) years, respectively. The proportion of patients receiving biologic treatment was significantly higher
in AS (46%) compared with PsA patients (28.8%); of these, 23.1% of AS and 22.2% of PsA patients
stopped/switched a biologic. There was a significant reduction in primary care involvement, sick notes
and disability living allowance for both AS and PsA patients following biologic initiation.
Conclusion. This real-world descriptive study confirms that patients treated with biologics have re-
duced disability and time off work despite being initiated 13 years after the first symptoms and
6 years after diagnosis.
Key words: psoriatic arthritis, ankylosing spondylitis, biologics, outcomes, treatment pathways, electronic
health records
Key messages
. Using real-world electronic data, we found that following biologic treatment reduced primary care utilization.
. Disability-related payments and sick notes issued in primary care also decreased following treatment.
. Biologics are effective in treating AS and PsA patients despite delays in diagnosis and treatment.
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PsA and AS are chronic inflammatory arthritic conditions
associated with significant morbidity and poorer quality
of life. The diagnosis of these conditions is often
delayed [1, 2] and this continues to be an issue in the
UK [3].
A recent study explored the patient pathway of re-
ceiving a diagnosis of AS from the patient perspective
in the USA. The sample was recruited online, compris-
ing self-reported AS-diagnosed individuals. The results
demonstrated a diagnosis delay, with back pain as the
presenting feature that led respondents to seek
treatment. Misdiagnosis was also an issue, with diag-
noses of back problems, sciatica, orthopaedic issues,
osteoarthritis, psychosomatic disorders and anxiety
and depression associated with a longer time to AS di-
agnosis. Significantly more women were misdiagnosed
with fibromyalgia and psychosomatic issues compared
with men [2].
Misdiagnosis and diagnosis delay of inflammatory ar-
thritic conditions can have a substantial impact; for in-
stance, in PsA, just a 6 month delay from symptom
onset to the first visit to a rheumatologist contributed to
greater peripheral joint erosion and worse function long-
term [4]. Moreover, AS and PsA have a negative impact
on quality of life and affect career choices and the ability
to work [5–8]. Reduced work productivity, work disability
and more absenteeism have been reported for both AS
[9–14] and PsA [8, 15, 16]. Additionally, a delay in diag-
nosis means that medications used to treat the condi-
tions are not accessed until later in the disease process,
further aggravating the health and social care impact of
AS and PsA.
The first line of treatment for AS and PsA is NSAIDs
followed by DMARDs for PsA patients. For severe dis-
ease, the National Institute of Health and Clinical
Excellence (NICE) treatment guidelines state that bio-
logic drugs can be prescribed when these treatments
have failed or are poorly tolerated [17, 18]. From clinical
trial data we know that PsA and AS patients respond
well to treatment with biologic agents [19, 20]. However,
little is known from real-world data on the effect of these
drugs on patient outcomes. In particular, the direct and
indirect healthcare effect of biologic initiation during
established disease is not clear. In this study we linked
data from primary and secondary care to specialty data
from rheumatology departments to follow the real-world
patient pathway from symptom onset to diagnosis to as-
sess the impact of AS and PsA on patients.
We explored treatments used, comorbidities and health
outcomes, primary care resource utilization in the form of
visits to the general practitioner (GP), productivity losses
from records of sick notes issued in primary care indicat-
ing individuals are not fit to work and disability payments,
which all demonstrate functional impairment.
Patients and methods
In Wales, UK, routinely collected electronic health
records were extracted and linked from the Secure
Anonymised Linkage (SAIL) Databank. The SAIL
Databank holds >1 billion anonymized records from
>90% of the people living in Wales, which has a pop-
ulation of 3 million. It uses a split-file approach to en-
sure anonymization and overcome issues of
confidentiality and disclosure in health-related data
warehousing. Demographic data from primary and
secondary care, as well as other data sources such as
cancer registries, social care and education are sent
to a partner organization, the National Health Service
Wales Informatics Service, where identifiable informa-
tion is removed; clinical data are sent directly to the
SAIL Databank and an individual is assigned an
encrypted anonymized linkage field (ALF). The ALF is
used to link anonymized individuals across datasets,
facilitating longitudinal analysis of an individual’s jour-
ney through multiple health, education and social
datasets. Data collected by physicians in primary care
are captured using Read codes (5-digit codes related
to diagnosis, medication and process of care codes)
[21]. Hospital inpatient and outpatient data are col-
lected in the Patient Episode Database for Wales,
which contains clinical information regarding patients’
hospital admissions, discharges, diagnoses and sur-
geries using the International Classification of
Diseases, Tenth Revision (ICD-10) clinical coding sys-
tem. Data from six rheumatology departments in
South Wales are also available. The rheumatology de-
partment data also uses the ICD-10 codes and con-
tains information pertaining to rheumatology
appointments, such as medications prescribed by
rheumatologists and rheumatology assessments.
Patients 18 years of age at diagnosis were identi-
fied from the rheumatology dataset by relevant ICD-10
codes present for AS (ICD-10: M45) and PsA (ICD-10:
L40.5). The rheumatology data was linked at the pa-
tient level to primary care data where Read codes
were also present for AS (N100.) and PsA (M160.,
M166, M1601, M1602, M160z), to ensure that patients
could be followed through their primary healthcare
records. Codes for AS were used in the absence of
codes available for axial SpA. Primary care data pro-
vided medications taken, comorbidities and healthcare
resource utilization. Data linkage to hospital admis-
sions data allowed surgical procedures and hospital-
izations to be explored. Data were included from 2009
to 2018 to coincide with optimum data coverage/bio-
logic prescription and available data.
Data held in the SAIL Databank are anonymized and
therefore no ethical approval was required. All data con-
tained in the SAIL Databank have permission from the
relevant Caldicott Guardian or Data Protection Officer.
This study was approved by the SAIL Databank
Information Governance Review Panel.












Exposures of interest included the medications used to
treat PsA and AS patients, including NSAIDs and
DMARDs, and whether the patient was receiving bio-
logic treatment or not.
Outcomes
Outcomes included commencing a biologic therapy,
healthcare resource utilization and receipt of UK govern-
ment disability payments. Biologic treatment failure was
defined as stopping/starting/switching to another bio-
logic. A biologic treatment was assumed to stop when
no further codes were present in the data and an alter-
native biologic treatment had codes succeeding the pre-
vious biologic. Healthcare resource utilization included
visits to primary care and sick notes issued by a GP
(primary care physician). UK government disability pay-
ments [Personal Independence Payments (PIP) or
Disability Living Allowance (DLA)] are issued to individu-
als with a disability and/or health conditions when there
are difficulties with daily living and mobility for
>3 months, with the expectation that these will continue
for at least a further 9 months.
Covariates of interest and confounding factors
The baseline covariates considered were age, sex, BMI,
level of social deprivation, disease duration, smoking
and alcohol use. In addition, comorbidities were identi-
fied from Read codes present in primary care health
records (cardiovascular disease, diabetes, hyperlipidae-
mia, hypertension, interstitial lung disease; see
Supplementary Table S1, available at Rheumatology
Advances in Practice online). ICD-10 codes for serious
infections (Supplementary Table S2, available at
Rheumatology Advances in Practice online) and National
Clinical Coding Standards OPCS-4 for orthopaedic sur-
gery (Supplementary Table S3, available at
Rheumatology Advances in Practice online) from hospital
admissions data were also included. Unfortunately,
acute phase reactants, ESR and C-reactive protein
measurements were unavailable at the time of analysis.
For a summary of the data source for all variables, see
Supplementary Table S4, available at Rheumatology
Advances in Practice online.
Statistical analysis
Descriptive statistics were used to examine the covari-
ate distribution at baseline. Cox proportional hazards
models were employed to calculate the hazard ratio
(HR) of factors associated with initiating biologic treat-
ment and biologic treatment failure in PsA and AS
patients, controlling for potential confounders.
Censoring occurred when a patient failed a biologic,
was lost to follow-up (i.e. moved out of the area and
longer contributed data) or died. Univariate analyses
were performed to determine significance and candidate
variables to be included in the Cox proportion hazards
models (inclusion threshold P< 0.05).
Results
Demographics
There were 641 and 1312 patients present in the rheu-
matology clinic with ICD-10 codes for AS and PsA, re-
spectively. The AS population was 24% (154/641)
female, compared with 51.8% (679/1312) for PsA
patients. The PsA population was significantly older [dif-
ference 3.9 (95% CI 2.6, 5.2)] and had significantly in-
creased BMI [difference 2.5 (95% CI 1.9, 3.1)] compared
with AS patients (Table 1).
The rate of GP involvement (including visits, telephone
consultations, letters, prescriptions and administrative
tasks) per annum was significantly higher in the PsA
patients compared with AS patients [difference 8.1 (95%
CI 4.9, 11.3)], while disability-related payments [differ-
ence 9.2 (95% CI 5.2, 13.3)] and sick notes [difference
6.6 (95% CI 3.5, 10)] were significantly higher in AS
patients compared with PsA patients (Table 1).
Presenting symptoms
The majority of AS and PsA patients had back pain
Read codes prior to diagnosis (93% and 94.4%, respec-
tively). With regard to peripheral joint pain symptoms
pre-diagnosis, PsA patients had a significantly higher
rate of this presenting symptom compared with AS
patients (88.6% and 82.7%, respectively). The average
time from onset of symptoms to diagnosis was longer
for those with back pain compared with those with pe-
ripheral joint symptoms [7.9 years (S.D. 5.5) and 6.1 (S.D.
5.7), respectively]. However, the reverse was true for
PsA; those with peripheral joint pain were diagnosed
1.6 years earlier than those with back pain [7.7 years
(S.D. 5.6) and 9.3 (S.D. 5.5), respectively] (Table 1).
NSAID and DMARD treatment
Prior to starting biologic therapy, NSAIDs were fre-
quently used in AS and PsA patients (95.6% and 93.7%,
respectively). Many of the AS patients were treated with
DMARDs prior to biologics [62.4% (184/295)] compared
with the majority of the PsA patients [89.4% (338/378)]
(Table 1).
Biologic initiation
Significantly more AS patients [46% (295/641)] were
treated with biologics compared with PsA patients
[28.8% (378/1312)]. The mean time to biologic treatment
from diagnosis was 6.3 years (S.D. 4.8) in AS patients
and 6.2 years (S.D. 4.6) in PsA patients (Table 1). Data on
biologic agents used for AS and PsA patients are avail-
able in Supplementary Figs S1 and S2, available at
Rheumatology Advances in Practice online.
Biologic treatment change/failure
The rate of biologic treatment failure, as defined by indi-
viduals who stopped, added or switched biologic
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medication, was 23.1% (68/295) in AS patients and
22.2% (84/378) in PsA patients (Table 1).
Comorbidities, alcohol use and smoking status
There was no significant difference in comorbidities, use
of alcohol and smoking status between AS and PsA
patients (Table 1).
Healthcare use pre- and post-biologic use
GP visits
Involvement with the GP (visits, prescriptions, adminis-
trative tasks) was significantly reduced from pre- to
post-biologic treatment for both AS [difference 60.9
(95% CI 44.2, 77.6)] and PsA [difference 64.4 (95% CI
44.9, 83.9)] (Table 2).
Rheumatology visits
Visits to the rheumatologist remained unchanged pre-
and post-biologic for AS and PsA patients [1.0 (S.D. 0.2)]
(Table 1)
Sick notes
The rate of sick notes issued in primary care within
1 year before commencing biologic therapy for AS and
PsA patients was 5.8% (17/295) and 5.3% (20/378), re-
spectively. These figures decreased the 1 year post-bio-
logic start date to less than five individuals (<1.3%)
having a sick note (Table 2).
Disability payments
Disability-related payments were issued to 15.9% of AS
patients and 15.6% of PsA patients within 1 year prior to
commencing biologic treatment. This rate decreased to
<1.3% 1 year following biologic treatment (Table 2).
Factors associated with commencing biologic
treatment
A Cox proportional hazards model showed two factors
that were associated with commencing biologic treat-
ment in AS patients: prior disability-related payments
[HR 4.26 (95% CI 3.02, 6.00)] and sick notes [HR 1.60
TABLE 1 Characteristics of AS and PsA patients
Characteristics AS (n 5 641) PsA (n 5 1312) Difference (95% CI)
Female, % (n) 24 (154) 51.8 (679) 27.7 (23.3, 31.9)*
BMI, mean (S.D.) 28 (5.6) 30.5 (6.7) 2.5 (1.9, 3.1)*
Townsend deprivation score, mean (S.D.)† 3.1 (1.5) 3.0 (1.5) 0.1 (0.2, 0)
Age at diagnosis, years, mean (S.D.) 42.6 (14) 46.5 (13.7) 3.9 (2.6, 5.2)*
Presenting back (AS) or peripheral (PsA) pain pre-diagnosis, % (n) 93 (596) 88.6 (1162) 4.4 (1.7, 6.9)*
Time from back/peripheral pain to diagnosis, years, mean (S.D.) 7.9 (5.5) 7.7 (5.6) 0.2 (0.3, 0.7)
Alcohol use, % (n) 86 (551) 87.7 (1150) 1.7 (1.4, 5.0)
Smoker, % (n) 11.4 (73) 9.1 (119) 2.3 (5.4, 0.5)
GP visits per annum, mean (S.D.) 50.6 (32.5) 58.7 (34.4) 8.1 (4.9, 11.3)*
Existing diabetes, % (n) 3.7 (24) 4.5 (59) 0.8 (1.3, 2.5)
Existing cardiovascular disease, % (n) 3.7 (24) 3.3 (43) 0.4 (2.4, 1.2)
Existing hyperlipidaemia, % (n) 5 (32) 6.3 (83) 1.3 (1.0, 3.4)
Existing hypertension, % (n) 19.2 (123) 23.6 (309) 4.4 (0.5, 8.1)
Hospitalised for serious infections, % (n) 5.9 (38) 6.9 (90) 0.9 (1.5, 3.1)
Issued disability living allowance, % (n) 27.5 (176) 18.3 (240) 9.2 (5.2, 13.3)*
Sick notes issued by GP, % (n) 16.2 (104) 9.6 (126) 6.6 (3.5, 10)*
Any use of NSAIDs in GP records, % (n) 96.7 (620) 94.3 (1237) 2.4 (0.4, 4.2)*
Any use of DMARDs in GP records, % (n) 41.2 (264) 82.3 (1018) 36.4 (31.9, 40.7)*
Prescribed a biologic, % (n) 46 (295) 28.8 (378) 17.2 (12.6, 21.8)*
Characteristics of patients administered biologics AS (n¼295) PsA (n¼378)
GP involvement within 1 year pre-biologic initiation, mean (S.D.)‡ 69.7 (143.5) 75.1 (167.4) 5.4 (18.6, 29.4)
GP involvement within 1 year post-biologic initiation, mean (S.D.) ‡ 8.8 (26.3) 10.7 (36.3) 1.9 (3.0, 6.8)
GP involvement per annum, mean (S.D.) ‡ 51.6 (31.2) 60.6 (31.8) 9 (4.2, 13.8)*
Visits to rheumatologist within 1 year pre-biologic, mean (S.D.) 1.0 (0.2) 1.0 (0.2) 0 (0.0, 0.0)
Visits to rheumatologist within 1 year post-biologic, mean (S.D.) 1.0 (0.2) 1.0 (0.2) 0 (0.0, 0.0)
NSAIDs pre-biologic use, % (n) 81 (239) 78.6 (297) 2.5(3.8, 8.5)*
Number of NSAIDs used pre-biologic, mean (S.D.) 11.3 (3.1) 11.5 (3.1) 0.2 (0.3, 0.7)
DMARDs pre-biologic use, % (n) 16.9 (50) 35.7 (135) 18.8 (12.1, 25)*
Number of DMARDs used pre-biologic, mean (S.D.) 2.5 (1.8) 3.0 (1.5) 0.5 (0.3, 0.8)*
Time to biologic from diagnosis, years, mean (S.D.) 6.3 (4.8) 6.2 (4.6) 0.1 (0.8, 0.6)
Biologic duration, years, mean (S.D.) 2.9 (2.7) 2.5 (2.7) 0.4 (0.1, 0.8)
Biologic treatment stop/change/fail, % (n) 23.1 (68) 22.2 (84) 0.9 (5.5, 7.3)
*P<0.05. †Where 1¼most affluent and 5¼most deprived. ‡Involvement includes face-to-face visit, telephone consultation,
prescription and administration (request for tests, letters).








ap/article/5/2/rkab042/6310184 by guest on 15 N
ovem
ber 2021
(95% CI 1.14, 2.24)] (Supplementary Table S5, available
at Rheumatology Advances in Practice online).
For PsA patients, factors associated with commencing
biologic therapy were prior disability-related payments
[HR 2.55 (95% CI 1.15, 5.66)] and an incremental in-
creased risk of commencing biologics per each addi-
tional DMARD used [HR 2.21 (95% CI 1.87, 2.60)]
(Supplementary Table S6, available at Rheumatology
Advances in Practice online).
Factors associated with biologic treatment failure
The duration of biologic treatment was the only signifi-
cant factor associated with both AS and PsA biologic
treatment failure in their respective Cox proportional
hazards models (see Supplementary Tables S7 and S8,
available at Rheumatology Advances in Practice online).
For AS patients, with each additional year of biologic
treatment there was an incremental increased risk of
treatment failure of 51% [HR 1.51 (95% CI 1.39, 1.64)]
(Supplementary Table S7, available at Rheumatology
Advances in Practice online). This was also the case for
PsA patients, with an increased risk of 32% for each ad-
ditional year of biologic treatment [HR 1.32 (95% CI
1.24, 1.42)] (Supplementary Table S8, available at
Rheumatology Advances in Practice online).
Discussion
Our real-world data found that the time from symptom
onset, either peripheral joint or back pain, to diagnosis
in patients with PsA and AS is 6–9 years. For AS, this is
similar to the findings from the DANBIO registry
(88 months) [22], while for PsA the delay is longer
(41 months).
The impact of AS and PsA on work disability has
been documented previously [8, 10, 11, 13–16, 23]. Sick
leave is reportedly high for AS patients, with 63%
experiencing at least one period of sick leave and 45%
experiencing recurrent sick leave [24]. For PsA, findings
from clinical trials and cohort studies estimate unem-
ployment rates between 20 and 50% and work disability
rates between 16 and 39% [8]. Registry data on AS
patients from the UK have demonstrated that biologics
provide greater improvements in presenteeism and work
impairment [25]. Our data demonstrate a decreased rate
of sick notes issued after biologic treatment.
The impact of work disability and sick leave is huge
for society and the individual. For instance, the indirect
costs associated with sick leave and work disability due
to AS are at least as high as direct costs [26]. In addi-
tion to costs associated with the loss of working hours,
early retirement and unpaid caregivers’ time are also
significant, and increased functional impairment is asso-
ciated with even greater costs of AS [27]. Predictors of
sick leave in AS are disease activity and physical func-
tion, however, only in AS patients with lower educational
attainment [24].
Here we found that the use of biologics is associated
with a reduction in sick notes issued in primary care in
both AS and PsA patients. This provides real-world evi-
dence from routinely collected health data confirming
the benefit of biologic treatment on work productivity as
observed in clinical trials, registry data, meta-analyses
and cohort studies [25, 28–30].
In addition, payments issued in the UK to assist with
chronic and prolonged disability were reduced after bio-
logics compared with before. This provides evidence
that in the real-world setting, biologics are associated
with improving disease symptoms and functional ability
in severe AS and PsA patients.
Healthcare visits/interactions with the GP deceased
significantly within 1 year of commencing biologic treat-
ment compared with the year preceding treatment, sug-
gesting optimal disease control and related reduced
healthcare utilization. Although it could be argued that
the patient is now seeing his/her secondary care physi-
cian more, causing a decrease in GP encounters, the
number of appointments in rheumatology clinics post-
biologics did not increase.
Biologic medications were more widely used in AS
patients compared with PsA patients. The prevalence of
biologics use is similar to that observed in other coun-
tries [31, 32]. The rate of treatment failure/change in the
biologic treatment regimen for all patients was 21%,
which is the same proportion of patients found to switch
TABLE 2 GP involvement, sickness and disability pre- and post-biologic treatment
Variable 1 year pre-biologic 1 year post-biologic Difference (95% CI)
GP involvement attended, mean (S.D.)
AS (n¼295) 69.7 (143.5) 8.8 (26.3) 60.9 (44.2, 77.6)*
PsA (n¼378) 75.1 (167.4) 10.7 (36.3) 64.4 (44.9, 83.9)*
Proportion of patients issued sick notes by GP, % (n)
AS (n¼295) 5.8 (17) <1.7 >4.1 (1.0, 7.5)*
PsA (n¼378) 5.3 (20) <1.4 >4.0 (1.4, 6.8)*
Proportion of patients receiving disability living allowance, % (n)
AS (n¼295) 15.9 (47) <1.7 >14.2 (9.9, 18.9)*
PsA (n¼378) 15.6 (59) <1.4 >14.3 (10.6, 18.4)*
*P<0.05. †Data suppressed to protect patient anonymity as <5 records.
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to a different biologic in a study conducted in the USA
using medical claims data [33]. In accordance with NICE
guidelines, AS patients commonly used NSAIDs while
PsA patients frequently used DMARDS prior to begin-
ning biologic medication.
The proportion of AS patients with early peripheral
joint pain observed in our study was higher than
reported elsewhere [34, 35]. However, a recent study
has observed high rates of presenting peripheral joint
pain in early, ‘pre-diagnosed AS’ [36]. In addition, the
proportion of PsA patients with early back pain is also
higher than expected in our study. However, there is a
lack of high-quality population epidemiology for compar-
ison. A recent MRI study detected sacroiliitis in 38% of
patients with PsA, which suggests this is an underrecog-
nized manifestation [37].
Biologic therapy has been shown to lead to short-
and long-term improvements in disease activity and
health-related quality of life in AS [38–40] and PsA [41–
43]. In PsA patients, treatment with biologics has been
shown to improve work disability, clinical outcomes and
participation in social activities [29, 30, 44].
Factors that were associated with commencing bio-
logics in AS patients were sick notes and disability pay-
ments, which are suggestive of poorly controlled
disease and impaired function. Similarly for PsA
patients, disability payments were also associated with
starting biologic treatment, in addition to increased
DMARDs used pre-biologics, which are also likely to in-
dicate increased disease activity and impaired function.
Biologic treatment failure was associated with increased
biologic treatment duration, as one might expect due to
increased chance of failure because of loss of effect
with sustained biologic treatment [45].
Strengths
This study uses real-life routinely collected health data.
As such, medical events are confirmed in the data with
the presence of clinical coding as opposed to relying on
participant memory of self-reported events. Using real-
life patient data from rheumatology centres in Wales,
the findings are also likely to be representative of indi-
viduals under the care of a rheumatologist in the UK
rather than, for instance, more severe patients who tend
to be enrolled in randomized controlled trials.
The findings that biologics reduce the rate of sick
notes (improving disease activity), reduces the need for
disability-related payments (improving disease activity
and functional ability) and reduces visits to the GP (im-
proving disease activity and reducing primary care
healthcare utilization) demonstrates their utility to im-
prove patient quality of life and reduce work disability in
AS and PsA patients.
Weaknesses
Treatment failure was not accessible to us from the rou-
tine data since end dates of treatments are not
recorded. As such, switching medication or adding
additional therapy was used as a proxy to define treat-
ment failure. We were unable to discriminate between
primary care encounters from the routine data, which
would have been useful to assess health resource utili-
zation. We were also not able to assess the dosage of
biologic medications, so we could not determine dose
escalation.
Conclusion
It is important to identify and remove barriers for the
timely diagnosis of AS and PsA to facilitate earlier diag-
nosis and treatment to help prevent disability and im-
prove quality of life. However, in a cohort of individuals
with a large diagnosis delay, the effect of biologics on
outcome, in particular, reduction of long-term sickness
as evidenced by decreased sick notes is extremely pos-
itive. Interventions aimed at reducing functional impair-
ment can help reduce work disability and the associated
costs while improving employment prospects and qual-
ity of life for AS and PsA patients.
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Severens JL. Impact of ankylosing spondylitis on sick
leave, presenteeism and unpaid productivity, and
estimation of the societal cost. Ann Rheum Dis 2010;69:
1123–8.
6 Webers C, Vanhoof L, van Genderen S et al.
Employment and the role of personal factors among
patients with ankylosing spondylitis: A Dutch cross-
sectional case-control study. RMD Open 2018;4:
e000680.
7 Castillo-Ortiz JD, Ramiro S, Landewé R et al. Work
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